[
    {
        "pregunta": "1. ¿Qué tratamientos farmacológicos se recomiendan condicionalmente para pacientes adultos con riesgo muy alto de fractura por GIOP?",
        "respuesta": "Para pacientes adultos con riesgo muy alto de fractura por osteoporosis glucocorticoide-inducida (GIOP), se **recomiendan condicionalmente los agentes anabólicos PTH/PTHrP** sobre los tratamientos antiresortivos (como bisfosfonatos y denosumab). Además, el denosumab (DEN) también está **condicionalmente recomendado** en esta población en alto riesgo, pero la preferencia específica es hacia PTH/PTHrP en riesgo muy alto.\n\nEn resumen:\n\n- **PTH/PTHrP:** recomendación condicional preferida en riesgo muy alto.\n- **Denosumab (DEN):** recomendación condicional en alto riesgo, puede considerarse.\n- **Bisfosfonatos (BP):** recomendación condicional en algunos casos, pero PTH/PTHrP es preferido en riesgo muy alto.\n\nEsta recomendación se basa en la limitada evidencia directa de prevención de fracturas, pero considerando la eficacia anabólica para mejorar la masa ósea en pacientes con riesgo muy alto.",
        "contexto": [
            "of benefits for treatment in the GIOP population. Because of these limitations, most of the recommendations in this guideline are conditional. Future studies in the treatment of GIOP should be powered to assess fracture risk reduction. Studies should focus on children and patients with CKD stage 4 and 5. As part of risk assessment, studies should explore the use of quantitative computed tomography (CT), bone finite element analysis from CT scans, and BMD measurements from CT colonography. It",
            "BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally recommended given lack of fracture prevention data in GIOP populations. For adults at high risk, we conditionally recommended DEN or PTH/PTHrP over BP. For adults at very high risk, we conditionally recommended PTH/PTHrP over antiresorptives We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. We conditionally recommend PTH/PTHrP over anti-resorptives in",
            "(ROM) | We strongly recommend OP treatment for those at moderate, high or very high risk of fracture. <br> We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. <br> We conditionally recommend PTH/PTHrP over anti-resorptives in patients at very high risk of fracture. <br> We conditionally recommend DEN$&amp; or PTH/PTHrP over oral and IV BP in high risk of fracture. <br> We conditionally recommend IV BP, ROM, RAL over no treatment",
            "in GIOP. We conditionally recommend PTH/PTHrP over anti-resorptives in patients at very high risk of fracture. We conditionally recommend DEN $& or PTH/PTHrP over oral and IV BP in high risk of fracture. We conditionally recommend IV BP, ROM, RAL over no treatment in high and very high risk of fracture. In moderate risk, we conditionally recommend BP, DEN, or PTH/PTHrP in no preferred order among these agents. Except in patients intolerant of other agents, we conditionally recommend against RAL",
            "(>0.1 mg/kg/day), BP therapy is warranted. For adults ≥40 years, the panel voted to give clinicians the ability to select an OP therapy based on the patient's specific comorbidities and preferences, BMD values, fracture history, and other characteristics, rather than rank ordering the medication recommendations. Fracture prevention data in GIOP is currently limited to oral BP and PTH. Anabolic agents may be the preferred initial therapy for those at very high risk for fracture based on BMD and"
        ]
    },
    {
        "pregunta": "2. Which osteoporosis medications are strongly recommended for adults ≥40 years with high or very high risk of fracture due to glucocorticoid-induced osteoporosis (GIOP)?",
        "respuesta": "Para adultos de 40 años o más con **alto o muy alto riesgo de fractura** debido a osteoporosis inducida por glucocorticoides (GIOP), la guía **recomienda fuertemente el uso de bisfosfonatos orales** (BPs) sobre no recibir tratamiento. Esto se basa en evidencia que muestra reducción de fracturas totales y vertebrales, así como aumento de la densidad mineral ósea en cadera y columna lumbar en comparación con calcio y vitamina D solamente.\n\nEn resumen:\n\n- **Bisfosfonatos orales:** recomendación fuerte para pacientes ≥40 años con alto o muy alto riesgo de fractura en GIOP.\n\nAunque los agentes anabólicos PTH/PTHrP y denosumab también son opciones, su uso está condicionalmente recomendado, especialmente PTH/PTHrP en riesgo muy alto. Sin embargo, la única recomendación fuerte basada en evidencia con datos de fractura es para bisfosfonatos orales.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "in GIOP For adults ≥40 years with high or very high fracture risk, we strongly recommended oral BP A strong recommendation for oral BP is based on studies showing a reduction in total and vertebral fractures at 24 months and increased hip and lumbar spine BMD compared to calcium and vitamin D alone in GIOP (evidence report, Appendix S3, page 16). For adults ≥40 years with high fracture risk, we conditionally recommend PTH/PTHrP or DEN over BP (PICO 1.4c-1.28.c). For adults ≥40 years with high",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "|For adults ≥40 years with low fracture risk, we strongly recommend against OP medications due to known risk of harms and no evidence of benefit.|Very low|4.4a–4.13a|91–101|\n|Adults receiving high-dose GC (initial dose≥30 mg/day for &gt;30 days or cumulative dose ≥5 g in 1 year) We conditionally recommend treating with PTH/PTHrP over anti-resorptives.|Low|6.1b–6.19a|120–141|\n|Oral BP are strongly recommended over no treatment.|Low|6.1b–6.19a|120–141|",
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we"
        ]
    },
    {
        "pregunta": "3. ¿Cuál es la dosis mínima de glucocorticoides a partir de la cual se recomienda evaluar el riesgo de osteoporosis inducida por glucocorticoides (GIOP)?",
        "respuesta": "La guía recomienda evaluar el riesgo de osteoporosis inducida por glucocorticoides (GIOP) en todos los adultos que inician o continúan terapia con glucocorticoides a una dosis **≥ 2.5 mg/día** de prednisona o su equivalente.",
        "contexto": [
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many",
            "associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline"
        ]
    },
    {
        "pregunta": "4. Which bone mineral density (BMD) T-score thresholds correspond to low, moderate, high, and very high fracture risk in glucocorticoid-treated adults?",
        "respuesta": "Los valores de la puntuación T de densidad mineral ósea (DMO) que corresponden a los distintos niveles de riesgo de fractura en adultos tratados con glucocorticoides según la información proporcionada son:\n\n- **Riesgo bajo:** DMO con puntuación T > −1.0  \n- **Riesgo moderado:** DMO con puntuación T entre −1.0 y −2.4  \n- **Riesgo alto:** DMO con puntuación T ≤ −2.5 pero > −3.5  \n- **Riesgo muy alto:** DMO con puntuación T ≤ −3.5  \n\nEstos valores se utilizan junto con otras variables clínicas (como FRAX ajustado, fracturas previas y dosis de glucocorticoides) para estratificar el riesgo de fractura en osteoporosis inducida por glucocorticoides.",
        "contexto": [
            "|High fracture risk|BMD t-score ≤−2.5 but &gt;−3.5 OR FRAX (GC Adjusted) 10-year risk of MOF ≥20% but &lt;30% or hip ≥3% but &lt;4.5%|-|\n|Moderate fracture risk|FRAX (GC-Adjusted) 10-year risk of MOF ≥10 and &lt;20%, hip &gt;1 and &lt;3% OR BMD t-score between −1 and −2.4|Continuing GC treatment ≥7.5 mg/day for ≥6 months AND BMD z-score &lt; −3 OR significant BMD loss (more than the least significant change of DXA)|",
            "|Low fracture risk|FRAX (GC-Adjusted) 10-year risk of MOF &lt;10%, hip &lt;1 %, BMD &gt;−1.0|None of the above risk factors other than GC treatment|\n|Recommended treatment strategy|Adults ≥40 years at moderate, high, or very high risk of fracture|Adults &lt;40 years at moderate or very high risk of fracture|\n|Calcium and vitamin D|Optimized intake of dietary and supplemental calcium and vitamin D based on age-appropriate US Recommended Dietary Allowances|-|",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "| <strong>High fracture risk</strong>                                       | BMD T score ≤ -2.5 but &gt; -3.5 OR FRAX® (GC-Adjusted</em>) 10-year risk of MOF ≥20% but &lt;30% or hip ≥3% but &lt;4.5% | BMD T score ≤ -2.5 but &gt; -3.5 OR FRAX® (GC-Adjusted*) 10-year risk of MOF ≥20% but &lt;30% or hip ≥3% but &lt;4.5% |",
            "| <strong>Very high fracture risk</strong>                                  | Prior OP fracture(s) OR BMD T score ≤ -3.5 OR FRAX® (GC-Adjusted<em>) 10-year risk of MOF ≥30% or hip ≥4.5% OR High GC ≥30 mg/day for &gt;30 days OR cumulative doses ≥5 g/year | Prior fracture(s) OR GC ≥30mg/day OR cumulative ≥5grams/year |"
        ]
    },
    {
        "pregunta": "5. For adults ≥40 years at moderate fracture risk receiving glucocorticoid therapy, what osteoporosis treatments are conditionally recommended?",
        "respuesta": "Para adultos de 40 años o más con **riesgo moderado de fractura** que están recibiendo terapia con glucocorticoides, **la información proporcionada no especifica recomendaciones condicionales concretas de tratamientos para osteoporosis en esta categoría de riesgo**. \n\nLas recomendaciones condicionales específicas descritas en la guía corresponden principalmente a pacientes con **alto o muy alto riesgo de fractura**, donde se mencionan agentes anabólicos PTH/PTHrP, denosumab y bisfosfonatos. \n\nEn resumen: **no hay datos suficientes en la información disponible para establecer tratamientos condicionales recomendados específicamente para pacientes con riesgo moderado de fractura con GIOP.**",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "The relative risk for vertebral fracture was 14 and for hip fractures was 3 with a dose of ≥30 mg per day and ≥ 5 g of cumulative use For adults <40 years receiving one or more courses of high-dose GC therapy (mean dose prednisone equivalent ≥30 mg daily for ≥30 days) or cumulative GC dose ≥5 g over 1 year, we conditionally recommend oral or IV BP, PTH/PTHrP, DEN. We conditionally recommended against RAL/ROM (PICO 6.4a,b-6.24a,b). In this younger population, PTH/ PTHrP and ROM should only be",
            "risk of osteoporotic fractures in children and youth ages 4 to 17 years (PICO 7.1a-7.5a). For children and youth ages 4 to 17 years with an osteoporotic fracture who are continuing treatment with chronic GC at a dose of ≥0.1 mg/kg/day for >3 months, treating with an oral or IV BP is conditionally recommended over no treatment.  This conditional recommendation to treat with oral or IV BP to prevent recurrent fractures is based on low-certainty evidence. Depending on the specific disease or cause"
        ]
    },
    {
        "pregunta": "6. What are the major considerations when deciding to use anabolic agents as initial therapy in glucocorticoid-induced osteoporosis?",
        "respuesta": "Las principales consideraciones al decidir el uso de agentes anabólicos (PTH/PTHrP) como terapia inicial en la osteoporosis inducida por glucocorticoides (GIOP) son las siguientes:\n\n- **Nivel de riesgo de fractura:** Los agentes anabólicos están recomendados condicionalmente como terapia preferida en pacientes con **riesgo muy alto de fractura**. Esto se basa en su capacidad anabólica para aumentar la masa ósea en comparación con tratamientos antiresortivos.\n\n- **Preferencia frente a otros tratamientos:** Aunque bisfosfonatos orales tienen una recomendación fuerte para pacientes con alto o muy alto riesgo, en el caso de riesgo muy alto, los agentes anabólicos PTH/PTHrP son preferidos condicionalmente sobre bisfosfonatos y denosumab.\n\n- **Evidencia clínica limitada:** La recomendación se basa en evidencia limitada directa de prevención de fracturas, pero considera la eficacia en mejorar la densidad mineral ósea y el balance positivo de remodelación ósea.\n\n- **Consideraciones prácticas:** El uso inicial de agentes anabólicos puede estar limitado por la disponibilidad, coste, perfil de efectos secundarios y la necesidad de administración subcutánea diaria.\n\nEn resumen, la terapia anabólica se plantea mayormente en pacientes con riesgo muy alto de fractura como opción preferida, valorando eficacia anabólica y gravedad del riesgo, en contraste con otras opciones antiresortivas que tienen recomendación sólida en riesgos altos y muy altos.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline"
        ]
    },
    {
        "pregunta": "7. ¿Cuáles son las categorías de riesgo de fractura establecidas en la guía para pacientes con osteoporosis inducida por glucocorticoides?",
        "respuesta": "Las categorías de riesgo de fractura establecidas en la guía para pacientes con osteoporosis inducida por glucocorticoides (GIOP) se definen según la densidad mineral ósea (DMO) y otros factores clínicos, con los siguientes umbrales de puntuación T:\n\n- **Riesgo bajo:** T-score > −1.0  \n- **Riesgo moderado:** T-score entre −1.0 y −2.4  \n- **Riesgo alto:** T-score ≤ −2.5 pero > −3.5  \n- **Riesgo muy alto:** T-score ≤ −3.5  \n\nEstos niveles se combinan con otros parámetros clínicos (como la dosis de glucocorticoides, el ajuste FRAX y antecedentes de fracturas) para estratificar el riesgo de fractura en adultos tratados con glucocorticoides.",
        "contexto": [
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many",
            "The relative risk for vertebral fracture was 14 and for hip fractures was 3 with a dose of ≥30 mg per day and ≥ 5 g of cumulative use For adults <40 years receiving one or more courses of high-dose GC therapy (mean dose prednisone equivalent ≥30 mg daily for ≥30 days) or cumulative GC dose ≥5 g over 1 year, we conditionally recommend oral or IV BP, PTH/PTHrP, DEN. We conditionally recommended against RAL/ROM (PICO 6.4a,b-6.24a,b). In this younger population, PTH/ PTHrP and ROM should only be"
        ]
    },
    {
        "pregunta": "8. What is the role of parathyroid hormone (PTH) or PTH-related protein (PTHrP) agonists in the management of GIOP?",
        "respuesta": "Los agonistas de la hormona paratiroidea (PTH) y la proteína relacionada con la PTH (PTHrP) tienen un papel condicionalmente recomendado en el manejo de la osteoporosis inducida por glucocorticoides (GIOP), especialmente en pacientes adultos con **riesgo muy alto de fractura**. Se sugieren como terapia preferida sobre los tratamientos antiresortivos (bisfosfonatos o denosumab) en esta población debido a su efecto anabólico que incrementa la masa ósea y reduce fracturas vertebrales.\n\nAspectos clave:\n\n- **Indicación principal:** Pacientes con riesgo muy alto de fractura, considerados la opción preferida condicionalmente frente a antiresortivos.  \n- **Efectividad:** Mejoran densidad mineral ósea en columna lumbar y cadera, además de reducir fracturas vertebrales a 36 meses, aunque no se ha demostrado reducción de fracturas no vertebrales.  \n- **Limitaciones:** Evidencia limitada directa en prevención de fracturas en GIOP; uso restringido por costes, vía de administración (subcutánea), y efectos secundarios.  \n- **Continuidad del tratamiento:** La discontinuación puede llevar a pérdida gradual del hueso ganado, que puede prevenirse con tratamiento posterior con bisfosfonatos o denosumab.\n\nEn resumen, los agonistas de PTH/PTHrP son una opción terapéutica valiosa y preferida condicionalmente en pacientes con GIOP y riesgo muy alto de fractura, destacándose por su capacidad de aumentar la masa ósea a través de un mecanismo anabólico.",
        "contexto": [
            "medication (PICO 13.4, 13.6). Discontinuation of PTH/PTHrP medication may lead to gradual loss of bone gained over 12 to 18 months, which can be prevented by treatment with BP or DEN 4 DISCUSSION The objective of this updated ACR guideline for the prevention and treatment of GIOP ( 25 We risk stratified patients as low, moderate, high or very high risk of fracture based on FRAX 10-year probability and DXA t-or z-scores (Table 1 2, 3, and5 Risk assessment in children, youths, and adults <40",
            "BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally recommended given lack of fracture prevention data in GIOP populations. For adults at high risk, we conditionally recommended DEN or PTH/PTHrP over BP. For adults at very high risk, we conditionally recommended PTH/PTHrP over antiresorptives We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. We conditionally recommend PTH/PTHrP over anti-resorptives in",
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we",
            "or poor absorption is suspected, based on low certainty evidence, we conditionally recommend treatment with IV BP, DEN, ROM, or PTH/PTHrP. Of note, use of PTH/PTHrP after long-term BP treatment has blunted anabolic response but still increases BMD. If DEN is the first agent, switching to PTH/PTHrP may lead to transient bone losses in the hip and spine and is not recommended 4 Recommendations for treatment when GC are discontinued (Figure 5 For adults taking OP therapy and discontinuing GC",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally"
        ]
    },
    {
        "pregunta": "9. ¿Qué precauciones se deben tener con la discontinuación del denosumab (DEN) en el tratamiento de GIOP?",
        "respuesta": "Al discontinuar el tratamiento con denosumab (DEN) en pacientes con osteoporosis inducida por glucocorticoides (GIOP), la guía advierte lo siguiente:\n\n- Existe un **riesgo de rápida pérdida ósea y fracturas vertebrales progresivas** tras la suspensión de DEN.\n- Por ello, se **recomienda fuertemente iniciar un tratamiento antiresortivo (p. ej., bisfosfonatos) inmediatamente después de discontinuar DEN**, idealmente comenzando el antiresortivo entre 6 y 7 meses después de la última dosis de DEN, para prevenir estas fracturas y la pérdida acelerada de densidad mineral ósea.\n- No seguir esta recomendación puede conducir a un aumento significativo en el riesgo de fractura vertebral.\n\nEn resumen, la principal precaución es asegurar la transición rápida a un antiresortivo tras la suspensión de denosumab para evitar pérdida ósea acelerada y fracturas vertebrales en pacientes con GIOP.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "after ≥12 months of therapy), we conditionally recommend continuing current OP therapy or switching to another class of OP medication (PICO 13.5-13.6). For adults ≥40 years continuing chronic GC who discontinue DEN, we strongly recommend starting an antiresorptive over not starting OP medication (PICO 13.1, 13.3, 13.5). DEN remains effective at longer than 10 years in patients with postmenopausal OP. However, discontinuation of DEN after two or more doses has been associated with rapid loss of",
            "medication (PICO 13.4, 13.6). Discontinuation of PTH/PTHrP medication may lead to gradual loss of bone gained over 12 to 18 months, which can be prevented by treatment with BP or DEN 4 DISCUSSION The objective of this updated ACR guideline for the prevention and treatment of GIOP ( 25 We risk stratified patients as low, moderate, high or very high risk of fracture based on FRAX 10-year probability and DXA t-or z-scores (Table 1 2, 3, and5 Risk assessment in children, youths, and adults <40",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "of DEN must be followed by a BP beginning at 6 to 7 months after the last DEN dose to prevent rapidly progressive vertebral fractures. Additionally, IV BP, DEN, and ROM have increased risk of atypical femur fractures and osteonecrosis of the jaw compared to oral BP Very low level evidence does not support using combination therapy (eg, PTH/PTHrP and DEN, PTH/PTHrP and BP) in GIOP. In patients with postmenopausal OP, studies have shown synergistic increases in BMD with combination of PTH with IV"
        ]
    },
    {
        "pregunta": "10. What is the recommended management of osteoporosis therapy in adults who discontinue glucocorticoids and have no new fragility fractures with a current BMD T-score ≥ -2.5?",
        "respuesta": "Para adultos con osteoporosis inducida por glucocorticoides que **suspenden la terapia con glucocorticoides, no presentan nuevas fracturas por fragilidad y tienen una puntuación T de densidad mineral ósea (DMO) ≥ -2.5**, la guía recomienda **suspender la terapia específica para osteoporosis y continuar con la suplementación de calcio y vitamina D**.\n\nSin embargo, cuando se interrumpen tratamientos con denosumab, agonistas de PTH/PTHrP o romosozumab, se **recomienda fuertemente iniciar terapia secuencial con antiresortivos** (por ejemplo, bisfosfonatos o raloxifeno) para evitar pérdida ósea acelerada y fracturas, incluso en ausencia de glucocorticoides activos.\n\nEn resumen:\n\n- Si no hay fracturas nuevas y T-score ≥ -2.5 al suspender glucocorticoides → **detener tratamiento para osteoporosis y continuar calcio y vitamina D**.  \n- Si se suspende denosumab, PTH/PTHrP o romosozumab → **iniciar tratamiento antiresortivo secuencial para prevenir pérdida ósea**.\n\nEsta recomendación se basa en la evidencia disponible y el balance beneficio-riesgo para el control de la osteoporosis inducida por glucocorticoides.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "|Low fracture risk|FRAX (GC-Adjusted) 10-year risk of MOF &lt;10%, hip &lt;1 %, BMD &gt;−1.0|None of the above risk factors other than GC treatment|\n|Recommended treatment strategy|Adults ≥40 years at moderate, high, or very high risk of fracture|Adults &lt;40 years at moderate or very high risk of fracture|\n|Calcium and vitamin D|Optimized intake of dietary and supplemental calcium and vitamin D based on age-appropriate US Recommended Dietary Allowances|-|",
            "discontinued (Figure 5 For adults taking OP therapy and discontinuing GC therapy, with no new fragility fracture and a current BMD t-score ≥-2.5, we strongly recommended stopping current OP therapy and continuing calcium and vitamin D. However, sequential therapy is strongly recommended after stopping DEN, PTH/PTHrP, and ROM (Figure 5 This recommendation is based on low-certainty evidence and on the balance of benefits and harms of continued treatment with OP medication. BP and RAL can be",
            "1 to 2 years allows providers to detect the least significant BMD change according to their DXA machine, triggering the need to start OP therapy. For adults continuing chronic GC ≥2.5 mg/day and assessed as moderate, high, or very high fracture risk who are continuing OP therapy ≥1 year, we strongly recommend fracture risk re-assessment every 1 to 2 years over no risk reassessment (PICO 9.5-9.12). Despite the low certainty of the evidence, this is a strong recommendation as good clinical"
        ]
    },
    {
        "pregunta": "11. When might switching from oral bisphosphonates to intravenous bisphosphonates, denosumab, romosozumab, or PTH/PTHrP be recommended in glucocorticoid-induced osteoporosis?",
        "respuesta": "La información proporcionada **no especifica recomendaciones concretas** sobre las situaciones clínicas o criterios precisos para cambiar de bisfosfonatos orales a bisfosfonatos intravenosos, denosumab, romosozumab o agonistas de PTH/PTHrP en el tratamiento de la osteoporosis inducida por glucocorticoides (GIOP).\n\nSin embargo, se indica que:\n\n- Los bisfosfonatos orales son la **terapia inicial fuertemente recomendada** en adultos ≥40 años con alto o muy alto riesgo de fractura.\n- Otros agentes, como bisfosfonatos intravenosos, denosumab, romosozumab y agonistas de PTH/PTHrP, son **opciones terapéuticas condicionadas** que pueden usarse como tratamiento inicial o subsecuente.\n- Al discontinuar denosumab, PTH/PTHrP o romosozumab, se debe iniciar terapia secuencial con bisfosfonatos para evitar pérdida ósea acelerada.\n\nEn síntesis, el cambio a otros agentes puede considerarse como opciones subsecuentes o en pacientes con riesgo muy alto (para PTH/PTHrP preferido condicionalmente), pero la guía no detalla situaciones clínicas específicas para indicar el cambio desde bisfosfonatos orales a otros tratamientos.\n\n**Respuesta:**  \nNo hay información suficiente en la guía proporcionada para definir específicamente las situaciones clínicas o criterios para cambiar de bisfosfonatos orales a bisfosfonatos IV, denosumab, romosozumab o agonistas de PTH/PTHrP en GIOP.",
        "contexto": [
            "<p>|Initial OP therapy|Subsequent OP therapy options|\n|---|---|\n|Oral/IV Bisphosphonate|DEN, PTH/PTHrP, ROM|\n|RAL|Oral or intravenous BP, PTH/PTHrP, DEN, ROM|\n|PTH/PTHrP|Oral or intravenous BP, DEN|\n|Denosumab|Oral or IV Bisphosphonate, ROM|\n|Romosozumab|Oral or IV Bisphosphonate, DEN|</p>",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally recommended given lack of fracture prevention data in GIOP populations. For adults at high risk, we conditionally recommended DEN or PTH/PTHrP over BP. For adults at very high risk, we conditionally recommended PTH/PTHrP over antiresorptives We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. We conditionally recommend PTH/PTHrP over anti-resorptives in",
            "| <strong>Recommended treatment strategy</strong>                            | Calcium and Vitamin D, Bisphosphonates (oral or IV), PTH/PTHrP Agonists, Denosumab, Raloxifene, Romosozumab | Calcium and Vitamin D, Bisphosphonates (oral or IV), PTH/PTHrP Agonists, Denosumab, Raloxifene, Romosozumab |",
            "or DEN over BP (PICO 1.4c-1.28.c). For adults ≥40 years with high fracture risk, we conditionally recommend IV or oral BP, PTH/PTHrP, or DEN over Raloxifene (RAL) or Romosozumab (ROM) (PICO 1.4c-1.28.c). High-certainty evidence indicates that oral BP prevents vertebral fractures in GIOP Compared to BP and RAL, PTH/PTHrP, DEN, and ROM require sequential therapy with an anti-resorptive agent to prevent bone losses. Discontinuation of DEN must be followed by a BP beginning at 6 to 7 months after"
        ]
    },
    {
        "pregunta": "12. How should treatment strategies differ for patients receiving high-dose glucocorticoids (≥30 mg/day for >30 days or cumulative ≥5 g/year)?",
        "respuesta": "La información proporcionada no contiene detalles específicos sobre las estrategias de tratamiento diferenciadas para pacientes que reciben glucocorticoides en dosis altas (≥30 mg/día por más de 30 días o acumulado ≥5 g/año). Por lo tanto, no es posible ofrecer una respuesta basada en la evidencia disponible.",
        "contexto": [
            "followed by 0.6 mg an hour later, with ongoing antiinflammatory therapy until the flare resolves). Based on similar efficacy between agents demonstrated in the NMA , the Voting Panel did not further prioritize between the first-line agents, noting that treatment selection should be driven by patient factors (e.g., comorbidity, access, past experience) as part of shared decisionmaking. Likewise, parenteral glucocorticoids were favored over alternative agents when oral dosing is not possible. In",
            "position statement: The duration of glucocorticoid therapy in EGPA should be guided by the patient's clinical condition, values, and preferences. There is insufficient published evidence to support a specific duration of glucocorticoid treatment, and thus, the length of glucocorticoid therapy should be determined based on each patient's clinical circumstances. Many patients with EGPA require some treatment with glucocorticoids, generally at a low dose, to maintain control of asthma and allergy",
            "<h1>Table 2. Whether to give or defer non-live attenuated vaccinations in patients taking glucocorticoids, regardless of disease activity</h1>\n\n<p>| |Influenza vaccination|Other non-live attenuated vaccinations|\n|---|---|---|\n|Prednisone ≤ 10 mg daily<em>|++ Give|++ Give|\n|Prednisone &gt; 10 mg and &lt; 20 mg</em>|+ Give|+ Give|\n|Prednisone ≥ 20 mg daily<em>|+ Give|+ Defer</em>*|</p>\n\n<p>*Or the equivalent dose of any other glucocorticoid formulation, or the equivalent pediatric dose.</p>",
            "<p>† For patients taking the equivalent of prednisone &lt;20 mg/day or &lt;2 mg/kg/day for patients weighing &lt;10 kg or alternate-day glucocorticoid therapy (i.e., “low-level immunosuppression” [15,68]), these low doses can be continued if vaccination is critical and the risk of a disease flare or adrenal insufficiency when the patient is not taking glucocorticoids is high.</p>",
            "with respect to glucocorticoid (GC) dosages, tapering strategies, use of disease modifying anti-rheumatic drugs (DMARDs) and duration of treatment. Up to 29-45% of patients with PMR do not adequately respond to GCs within 3-4 weeks. Relapses and long-term GC dependency are common Primary objective of the recommendations. These recommendations are intended for the management of patients with PMR in various settings and are based on clinical evidence and expert opinion including informed patient"
        ]
    },
    {
        "pregunta": "13. What fracture risk assessment tools or adjustments are suggested for patients on glucocorticoids?",
        "respuesta": "Para pacientes que reciben glucocorticoides, la evaluación del riesgo de fractura incluye las siguientes herramientas y ajustes recomendados:\n\n- **Evaluación clínica del riesgo de fractura** considerando historia y dosis de glucocorticoides, duración y patrón de uso, antecedentes de fracturas (traumáticas, por fragilidad o asintomáticas), historial de caídas, antecedentes familiares (por ejemplo, fractura de cadera en padres), peso corporal bajo o pérdida significativa de peso, tabaquismo, consumo de alcohol, hipogonadismo, enfermedades tiroideas, hiperparatiroidismo y presencia de fragilidad.\n\n- **Uso de la herramienta FRAX ajustada para glucocorticoides**, ya que FRAX estándar no incluye el efecto completo de los glucocorticoides en el riesgo fracturario. El ajuste busca incrementar el riesgo calculado para reflejar mejor el impacto del tratamiento con glucocorticoides.\n\n- **Medición de densidad mineral ósea (DMO)**, preferentemente con absorciometría dual de rayos X (DXA), idealmente combinada con una evaluación vertebral con imágenes (VFA) o radiografía espinal para detectar fracturas vertebrales asintomáticas.\n\n- La evaluación inicial debe realizarse lo antes posible, preferentemente dentro de los primeros 6 meses tras el inicio de glucocorticoides.\n\nEn resumen, la evaluación del riesgo de fractura en pacientes con uso de glucocorticoides debe ser integral, incluyendo ajustes en la herramienta FRAX y evaluación por densitometría ósea con imágenes vertebrales, así como una valoración clínica detallada de factores de riesgo adicionales.",
        "contexto": [
            "or continuing GC therapy, despite the low certainty of the evidence. Initial assessment should occur as soon as possible within 6 months of GC therapy initiation. Clinical fracture risk assessment includes dose, duration, and pattern of GC use, alcohol use, smoking history, hypogonadism, history of prior fractures (traumatic, fragility, asymptomatic), low body weight, significant weight loss, parental history of hip fracture, fall history, thyroid disease, hyperparathyroidism, rheumatoid",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "|Clinical fracture risk assessment|History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, FRAX with GC adjustment, BMD with VFA or spinal x-ray|History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, BMD with VFA or spinal x-ray (FRAX not validated at age &lt;40 years)|",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day"
        ]
    },
    {
        "pregunta": "14. What is the risk associated with discontinuation of denosumab after two or more doses, and what is the recommended follow-up treatment?",
        "respuesta": "El riesgo asociado con la discontinuación de denosumab (DEN) tras dos o más dosis es la **pérdida rápida de densidad mineral ósea (DMO) y el desarrollo de nuevas fracturas vertebrales de compresión**, que pueden presentarse tan pronto como 7 a 9 meses después de la última dosis.\n\nEl tratamiento de seguimiento recomendado es iniciar **entre 6 y 9 meses después de la última dosis de denosumab** un tratamiento antiresortivo, preferiblemente con bisfosfonatos orales o intravenosos (BP) o romosozumab (ROM), para prevenir la pérdida ósea acelerada y las fracturas vertebrales.\n\nEn resumen:  \n- **Riesgo:** rápida pérdida ósea y fracturas vertebrales tras suspensión de DEN.  \n- **Recomendación:** comenzar tratamiento antiresortivo (BP o ROM) de forma temprana (6-9 meses después de la última dosis) para evitar complicaciones.",
        "contexto": [
            "of DEN after two or more doses has been associated with rapid loss of BMD and development of new vertebral compression fractures as soon as 7 to 9 months after the last DEN dose. As such, 6 to 9 months after the last dose of DEN, BP or ROM therapy is recommended For adults ≥40 years discontinuing chronic GC treatment who have completed a course of a PTH/PTHrP, we conditionally recommend starting BP over not starting an OP medication (PICO 13.4, 13.6). Discontinuation of PTH/PTHrP medication may",
            "be assessed. Once excluded, no dose adjustment is needed when prescribing DEN, PTH/PTHrP, or romosozumab (ROM). © 2022 American College of Rheumatology. All rights reserved.",
            "<h1>Sequential Treatments Recommended When Initial OP Therapy and GC are Discontinued and at Low or Moderate Risk</h1>\n\n<p>|Initial OP therapy|Subsequent OP therapy options|\n|---|---|\n|Oral/IV Bisphosphonate|No subsequent OP therapy needed|\n|RAL|No subsequent OP therapy needed|\n|PTH/PTHrP|Oral or IV Bisphosphonate|\n|Denosumab|Oral or IV Bisphosphonate|\n|Romosozumab|Oral or IV Bisphosphonate|</p>\n\n<h1>Sequential treatments when a new fracture occurs after ≥12 months of initial OP therapy</h1>",
            "after ≥12 months of therapy), we conditionally recommend continuing current OP therapy or switching to another class of OP medication (PICO 13.5-13.6). For adults ≥40 years continuing chronic GC who discontinue DEN, we strongly recommend starting an antiresorptive over not starting OP medication (PICO 13.1, 13.3, 13.5). DEN remains effective at longer than 10 years in patients with postmenopausal OP. However, discontinuation of DEN after two or more doses has been associated with rapid loss of",
            "including thrombosis, fatal stroke, major cardiovascular events, and death (PICO 1.6b, 1.10b, 1.12b, 1.16b, 1.17b, 1.21b, 1.22b, 1.23b, 1.24b, 1.25b, 1.28b, 2.9, 2.14, 2.18, 2.21). Multiple studies have shown that 12 months of ROM followed by an anti-resorptive agent (BP or DEN) for 12 month prevents fractures in patients with postmenopausal OP when compared to antiresorptive agent only In adults with low fracture risk, we strongly recommend against adding oral or IV BP, PTH/PTHrP, RAL, DEN, or"
        ]
    },
    {
        "pregunta": "15. What fracture types are included in the definition of major osteoporotic fractures (MOF) in GIOP?",
        "respuesta": "Las fracturas mayores por osteoporosis (MOF, por sus siglas en inglés) en el contexto de la osteoporosis inducida por glucocorticoides (GIOP) incluyen las **fracturas no traumáticas o patológicas** de los siguientes sitios:\n\n- Columna vertebral (espina)  \n- Cadera  \n- Muñeca  \n- Húmero\n\nEstas localizaciones se consideran en la definición de fracturas mayores osteoporóticas según la guía.",
        "contexto": [
            "| <strong>Major osteoporotic fracture (MOF)</strong>                        | Non-traumatic or pathological fractures of the spine, hip, wrist, or humerus | Non-traumatic or pathological fractures of the spine, hip, wrist, or humerus |",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "<p>|Term|Adults ≥40 years of age|Adults &lt;40 years of age|\n|---|---|---|\n|MOF|Nontraumatic or pathological fractures of the spine, hip, wrist, or humerus|Nontraumatic or pathological fractures of the spine, hip, wrist, or humerus|",
            "| <strong>Very high fracture risk</strong>                                  | Prior OP fracture(s) OR BMD T score ≤ -3.5 OR FRAX® (GC-Adjusted<em>) 10-year risk of MOF ≥30% or hip ≥4.5% OR High GC ≥30 mg/day for &gt;30 days OR cumulative doses ≥5 g/year | Prior fracture(s) OR GC ≥30mg/day OR cumulative ≥5grams/year |",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day"
        ]
    },
    {
        "pregunta": "16. How is the FRAX tool adjusted for glucocorticoid use when assessing fracture risk in adults ≥40 years old?",
        "respuesta": "Para adultos de 40 años o más que reciben glucocorticoides, la herramienta FRAX se ajusta para reflejar el aumento del riesgo de fractura debido al uso de glucocorticoides de la siguiente manera:\n\n- Si la dosis de glucocorticoides es **mayor a 7.5 mg/día de prednisona o equivalente**, se multiplica el riesgo a 10 años calculado por FRAX de fracturas mayores osteoporóticas (MOF) por **1.15**.\n\n- Asimismo, el riesgo de fractura de cadera se multiplica por **1.2**.\n\nEste ajuste busca compensar que el FRAX estándar no incluye completamente el efecto de los glucocorticoides en el riesgo fracturario, mejorando así la precisión de la estratificación del riesgo en estos pacientes.",
        "contexto": [
            "|Clinical fracture risk assessment|History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, FRAX with GC adjustment, BMD with VFA or spinal x-ray|History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, BMD with VFA or spinal x-ray (FRAX not validated at age &lt;40 years)|",
            "|Low fracture risk|FRAX (GC-Adjusted) 10-year risk of MOF &lt;10%, hip &lt;1 %, BMD &gt;−1.0|None of the above risk factors other than GC treatment|\n|Recommended treatment strategy|Adults ≥40 years at moderate, high, or very high risk of fracture|Adults &lt;40 years at moderate or very high risk of fracture|\n|Calcium and vitamin D|Optimized intake of dietary and supplemental calcium and vitamin D based on age-appropriate US Recommended Dietary Allowances|-|",
            "| <strong>FRAX® GC correction</strong>                                      | If GC dose is &gt;7.5 mg/day, multiply the 10-year risk of major osteoporotic fracture by 1.15 and the hip fracture risk by 1.2 | <em>Not applicable as FRAX® is not validated in this age group</em> |",
            "all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day for >3 months, we strongly recommended initial clinical fracture risk assessment including symptomatic and asymptomatic fracture history, FRAX (age ≥40 only), and BMD with VFA or spine x-rays over no assessment (PICO 8.1-8.4). These strong recommendations are based on good clinical practice and the need for clinicians to risk stratify patients beginning or continuing GC therapy, despite the low certainty of the evidence.",
            "| <strong>Clinical fracture risk assessment</strong>                        | History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, FRAX® with GC adjustment, BMD with VFA or spinal x-ray | History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, BMD with VFA or spinal x-ray (FRAX® not validated at age &lt;40 years) |"
        ]
    },
    {
        "pregunta": "17. Why is switching from denosumab to PTH/PTHrP not recommended in glucocorticoid-induced osteoporosis?",
        "respuesta": "La información proporcionada no incluye datos específicos ni recomendaciones acerca de cambiar de denosumab a agonistas de PTH/PTHrP en el tratamiento de osteoporosis inducida por glucocorticoides (GIOP). Por lo tanto, no es posible ofrecer una respuesta basada en la evidencia disponible sobre por qué no se recomendaría dicho cambio.",
        "contexto": [
            "BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally recommended given lack of fracture prevention data in GIOP populations. For adults at high risk, we conditionally recommended DEN or PTH/PTHrP over BP. For adults at very high risk, we conditionally recommended PTH/PTHrP over antiresorptives We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. We conditionally recommend PTH/PTHrP over anti-resorptives in",
            "|PTH/PTHrP Agonists (TER, ABL, Anti-RANKL, DEN)|We conditionally recommend PTH/PTHrP over anti-resorptives in patients at very high risk of fracture. We conditionally recommend DEN§# or PTH/PTHrP over oral and IV BP in high risk of fracture. In moderate risk, we conditionally recommend BP, DEN, or PTH/PTHrP in no preferred order among these agents.|-|",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "in GIOP. We conditionally recommend PTH/PTHrP over anti-resorptives in patients at very high risk of fracture. We conditionally recommend DEN $& or PTH/PTHrP over oral and IV BP in high risk of fracture. We conditionally recommend IV BP, ROM, RAL over no treatment in high and very high risk of fracture. In moderate risk, we conditionally recommend BP, DEN, or PTH/PTHrP in no preferred order among these agents. Except in patients intolerant of other agents, we conditionally recommend against RAL",
            "very high risk of fracture. We conditionally recommend DEN §# or PTH/PTHrP over oral and IV BP in high risk of fracture. In moderate risk, we conditionally recommend BP, DEN, or PTH/PTHrP in no preferred order among these agents. - Selective estrogen receptor modifier (RAL), Antisclerostin (ROM) We conditionally recommend IV BP, ROM, RAL over no treatment in high and very high risk of fracture. Except in patients intolerant of other agents, we conditionally recommend against RAL due to harms of"
        ]
    },
    {
        "pregunta": "18. Why should bisphosphonates be avoided in patients with advanced CKD undergoing treatment for glucocorticoid-induced osteoporosis?",
        "respuesta": "Los bisfosfonatos deben evitarse en pacientes con enfermedad renal crónica avanzada con una tasa de filtración glomerular (eGFR) menor a 35 ml/min porque en este contexto hay un mayor riesgo de desarrollar enfermedades metabólicas óseas asociadas a la insuficiencia renal, como osteodistrofia renal (incluyendo enfermedad ósea adinámica, osteomalacia, osteítis fibrosa quística y osteodistrofia urémica mixta).\n\nPor esta razón, se recomienda realizar una evaluación especializada por expertos en enfermedad ósea metabólica para descartar estas condiciones antes de iniciar tratamiento con bisfosfonatos en pacientes con función renal severamente deteriorada.\n\nUna vez descartadas dichas entidades, no se requiere ajuste de dosis, pero en general, se usa con precaución o se evita el uso de bisfosfonatos en pacientes con eGFR < 35 ml/min debido al riesgo incrementado de complicaciones óseas asociadas al deterioro renal.\n\nEn resumen:\n\n- **eGFR < 35 ml/min:** aumento del riesgo de enfermedad ósea metabólica inducida por insuficiencia renal.  \n- **Bisfosfonatos:** generalmente se deben evitar o usar con mucha precaución.  \n- **Recomendación:** evaluación especializada para descartar enfermedades óseas específicas antes de considerar bisfosfonatos.",
        "contexto": [
            "= Use with caution in women who may become pregnant due higher potency and longer half-life in fetal bones; % Avoid in young adults with open growth plates; & Use with caution in women of child bearing potential due to potential fetal harm. Avoid pregnancy for 5 months after last dose. Osteoporosis Medications for Patients with Chronic Kidney Disease or Following Renal Transplant Bisphosphonates should generally not be used in patients with an eGFR < 35 ml/min. When eGFR is < 35 ml/min, the",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "used in patients with an eGFR < 35 ml/min. When eGFR is < 35 ml/min, the risk of renal osteodystrophy, including adynamic bone disease, osteomalacia, osteitis fibrosa cystica and mixed uremic osteodystrophy, is increased. As such, metabolic bone disease expert evaluation for chronic kidney disease-mineral and bone disorder (CKD-MBD) is conditionally recommended to exclude these conditions. Hyperparathyroidism should also be assessed. Once excluded, no dose adjustment is needed when prescribing",
            "D supplementation have been suggested in other contexts Bisphosphonates are strongly recommended against in patients with knee, hip, and/or hand OA. Though a single small study of an oral bisphosphonate suggested a potential analgesic benefit in OA, the preponderance of data shows no improvement in pain or functional outcomes. Glucosamine is strongly recommended against in patients with knee, hip, and/or hand OA. Pharmaceutical-grade preparations of glucosamine are available and have been",
            "harms including increased myocardial infarction, stroke and death BP = bisphosphonate; PTH = parathyroid hormone; PTHrP = PTH-related protein; RANKL = Receptor activator of NF-κβ-Ligand; BMD = bone mineral density; GC= glucocorticoid; FRAX® = https//www.shef.ac.uk/FRAX/Tool.jsp; MOF = major osteoporotic fracture; * FRAX® GC correction example: if hip fracture risk is 2.0% multiply by 1.2 for adjusted risk = 2.4%; $ = Use with caution in women who may become pregnant due higher potency and"
        ]
    },
    {
        "pregunta": "19. ¿Qué efectos adversos importantes se asocian con el uso de bisfosfonatos intravenosos, denosumab y romosozumab en el tratamiento de la osteoporosis inducida por glucocorticoides?",
        "respuesta": "La información proporcionada no detalla específicamente los efectos adversos importantes asociados con el uso de bisfosfonatos intravenosos, denosumab y romosozumab en el tratamiento de la osteoporosis inducida por glucocorticoides (GIOP).\n\nSin embargo, en términos generales y basados en conocimientos estándares incluidos en la guía:\n\n- **Bisfosfonatos intravenosos:** Pueden asociarse con reacciones en el lugar de administración (síndrome pseudogripal), riesgos renales en pacientes con insuficiencia renal avanzada, y muy raramente osteonecrosis de mandíbula y fracturas atípicas femorales.\n\n- **Denosumab:** Riesgo importante de pérdida ósea acelerada y fracturas vertebrales múltiples tras su discontinuación si no se sigue con tratamiento antiresortivo. Pueden afectar el equilibrio inmunológico, aunque la guía no menciona eventos específicos en GIOP.\n\n- **Romosozumab:** Asociado con riesgo potencial de eventos cardiovasculares mayores (infarto, accidente cerebrovascular y muerte), por lo que su uso debe considerarse con precaución, aunque no está aprobado formalmente para GIOP según la información disponible.\n\nDado que esta información no está detallada en la guía presentada, se recomienda consultar fuentes específicas para una descripción pormenorizada de los perfiles de seguridad de estos fármacos en GIOP.",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "initial therapy for those at very high risk for fracture based on BMD and vertebral fracture prevention superiority compared to anti-resorptives in patients with very high risk postmenopausal OP. Of note, abaloparatide and ROM are not approved in GIOP, and we recognize it may be difficult to access these medications for GIOP. The panel specifically noted that the potential harms of RAL (venous thromboembolism [VTE] and fatal stroke) and ROM (major myocardial infarction, stroke, and death) would",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "including thrombosis, fatal stroke, major cardiovascular events, and death (PICO 1.6b, 1.10b, 1.12b, 1.16b, 1.17b, 1.21b, 1.22b, 1.23b, 1.24b, 1.25b, 1.28b, 2.9, 2.14, 2.18, 2.21). Multiple studies have shown that 12 months of ROM followed by an anti-resorptive agent (BP or DEN) for 12 month prevents fractures in patients with postmenopausal OP when compared to antiresorptive agent only In adults with low fracture risk, we strongly recommend against adding oral or IV BP, PTH/PTHrP, RAL, DEN, or"
        ]
    },
    {
        "pregunta": "20. What lifestyle modifications are recommended alongside pharmacologic treatment for prevention of glucocorticoid-induced osteoporosis?",
        "respuesta": "La información proporcionada no detalla específicamente las **modificaciones en el estilo de vida** recomendadas junto con el tratamiento farmacológico para la prevención de osteoporosis inducida por glucocorticoides (GIOP).\n\nSin embargo, basándonos en el enfoque general para la prevención de osteoporosis, suelen recomendarse medidas habituales como:\n\n- Mantener una ingesta adecuada de calcio y vitamina D.  \n- Realizar ejercicio físico regular, especialmente actividades que promuevan la salud ósea (ejercicio de carga y de fuerza).  \n- Evitar el consumo excesivo de alcohol y el tabaquismo.  \n- Minimizar el uso y la dosis de glucocorticoides cuando sea posible.\n\nEstas recomendaciones generales suelen acompañar el tratamiento específico con fármacos para GIOP, aunque no están descritas de forma explícita en la guía consultada.\n\nEn resumen: **No hay información específica disponible en la guía provista acerca de modificaciones en el estilo de vida para la prevención de osteoporosis inducida por glucocorticoides.**",
        "contexto": [
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      E6CF781F3D07C386647CEFDED26B8578  A strong recommendation was made to use oral bisphosphonates (BPs) over no treatment for adults ≥40 years receiving long-term GCs, at high and very high risk for fracture, based on available fracture data in GIOP populations. Other agents including intravenous BPs, PTH/PTHrP, and denosumab (DEN) are also options and are conditionally",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis      895E00BE431C5D109F968BA8D0506240 10.1002/acr.25240 Submitted for publication December 1, 2022; accepted in revised form July 3, 2023.  INTRODUCTION Glucocorticoids (GCs) remain a common therapeutic modality for patients with a variety of diseases. Prevention of GC-induced bone loss and fractures has been a focus of the American College of Rheumatology (ACR) for many",
            "has been a focus of the American College of Rheumatology (ACR) for many years because patients with osteoporotic fractures have increased risk of morbidity and mortality Despite increasing treatment options to prevent and treat glucocorticoid-induced osteoporosis (GIOP), many GC-treated patients are not evaluated or treated, resulting in preventable fractures The ACR first published recommendations for prevention and treatment of GIOP in 1996 METHODS This guideline follows the ACR guideline",
            "associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not"
        ]
    }
]